Noyabr, 2025-Yil
94
NEUROPROTECTIVE STRATEGIES IN GLAUCOMA: CURRENT EVIDENCE AND
FUTURE DIRECTIONS
Jalalova Dilfuza Zuhridinovna
Scientific supervisor.
Department of Ophthalmology, Samarkand State Medical University
Hatamova Ugʻiloy
Samarkand State Medical University, Department of Ophthalmology,
2st year clinical ordinator.
https://doi.org/10.5281/zenodo.17583894
Annotation.
Glaucoma, a leading cause of irreversible blindness worldwide, is
characterized by progressive optic nerve degeneration and loss of retinal ganglion cells.
Traditional treatments focus mainly on lowering intraocular pressure (IOP), yet
neurodegeneration often continues even with controlled IOP. This article reviews the emerging
neuroprotective strategies in glaucoma management, emphasizing pharmacological agents, gene
therapy, mitochondrial stabilization, and stem-cell-based approaches. Evidence suggests that
neuroprotection targeting excitotoxicity, oxidative stress, inflammation, and impaired axonal
transport can preserve retinal ganglion cell integrity and visual function. Current research also
highlights the potential of neurotrophic factors, calcium channel blockers, and antioxidant
compounds as adjuncts to conventional therapy. Although significant progress has been made,
translating neuroprotective mechanisms into clinical application remains challenging. Future
directions should focus on combination therapies integrating IOP control and neuronal
preservation to halt disease progression and improve long-term outcomes in glaucoma patients.
Keywords
: Glaucoma, neuroprotection, retinal ganglion cells, oxidative stress,
neurotrophic factors, apoptosis, intraocular pressure, mitochondrial dysfunction, optic nerve,
visual preservation.
Introduction
Glaucoma represents a complex neurodegenerative optic neuropathy that
results in irreversible visual loss due to damage to retinal ganglion cells (RGCs) and their axons.
Elevated intraocular pressure remains the most important risk factor; however,
glaucomatous damage can develop or progress despite adequate pressure control, suggesting that
mechanisms beyond mechanical stress contribute to neurodegeneration. Pathophysiological
processes include glutamate excitotoxicity, mitochondrial dysfunction, oxidative stress,
neuroinflammation, and reduced neurotrophic support. These processes converge to induce
apoptosis of RGCs and progressive visual field loss. The neuroprotective concept aims to directly
target neuronal survival and prevent or delay irreversible optic nerve damage, thereby
complementing traditional pressure-lowering therapies. Neuroprotective strategies include
pharmacological interventions such as NMDA receptor antagonists, calcium channel blockers, and
antioxidants, as well as novel modalities like gene therapy and stem cell transplantation. The goal
is to sustain RGC function, preserve axonal integrity, and maintain visual performance. This paper
reviews contemporary evidence for neuroprotective strategies in glaucoma and explores future
prospects for integrating these approaches into comprehensive disease management.
Noyabr, 2025-Yil
95
Materials and Methods
A systematic review of recent studies from 2010 to 2024 was
conducted using PubMed, Scopus, and Web of Science databases. Keywords used included
“glaucoma,” “neuroprotection,” “retinal ganglion cell,” “oxidative stress,” and “neurotrophic
factors.” Randomized controlled trials, meta-analyses, and experimental studies investigating
neuroprotective mechanisms or therapeutic interventions were included. Exclusion criteria
comprised studies without measurable neuroprotective outcomes, non-English publications, and
reviews lacking primary data. Data extraction focused on neuroprotective mechanisms, therapeutic
efficacy, safety profiles, and translational potential. Comparative analysis was performed to
evaluate both established and emerging neuroprotective compounds in preclinical and clinical
contexts. Parameters assessed included rate of RGC loss, optic nerve integrity, visual field
progression, and patient-reported outcomes where available.
Results
The review included 52 studies comprising 22 clinical trials and 30 experimental
models. Evidence indicated that lowering IOP alone slowed but did not fully prevent RGC
degeneration. NMDA receptor antagonists such as memantine demonstrated significant
neuroprotective effects in animal models, although human trials produced mixed results due to
dosage and duration limitations. Calcium channel blockers, including nimodipine, improved
ocular blood flow and RGC survival. Brimonidine, an α2-adrenergic agonist, exhibited both IOP-
lowering and direct neuroprotective effects through modulation of apoptotic signaling and
neurotrophic factor release. Antioxidant compounds like coenzyme Q10, Ginkgo biloba extract,
and resveratrol reduced oxidative stress and preserved mitochondrial function. Gene therapy using
vectors encoding brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF)
showed promise in restoring axonal transport and enhancing cell survival. Experimental stem cell
therapies demonstrated the potential to replace damaged RGCs and promote endogenous
regeneration through paracrine signaling. Overall, combination therapies targeting both IOP and
neurodegeneration yielded superior outcomes in visual preservation compared to monotherapies.
Discussion
The findings reinforce that glaucoma is a multifactorial neurodegenerative
disease requiring multidimensional management beyond pressure reduction. Neuroprotection
represents a vital adjunctive strategy capable of mitigating progressive optic nerve damage. The
mechanisms underlying RGC death include excitotoxicity from glutamate accumulation, increased
intracellular calcium, oxidative injury from mitochondrial dysfunction, and proinflammatory
cytokine activity. Pharmacological neuroprotection, though promising in experimental settings,
faces translational challenges due to limited bioavailability, variability in patient response, and
difficulty in monitoring neuronal survival in vivo. Brimonidine remains the only agent with partial
clinical validation, while novel therapies such as BDNF gene delivery and stem cell-based
neuroregeneration are under investigation. Mitochondrial stabilizers and anti-inflammatory
modulators further contribute to maintaining cellular homeostasis under glaucomatous stress. The
integration of biomarkers such as neurofilament light chain and advanced imaging modalities like
optical coherence tomography (OCT) may enhance early detection of neurodegenerative changes
and facilitate assessment of neuroprotective efficacy. Future research must prioritize combination
strategies uniting mechanical, metabolic, and neurotrophic interventions, supported by robust
clinical trial design and long-term follow-up. The ultimate objective is to preserve visual function
and quality of life for patients with glaucoma by preventing irreversible neuronal loss.
Noyabr, 2025-Yil
96
Conclusion
Neuroprotective strategies offer a promising frontier in glaucoma management
by addressing mechanisms of optic nerve degeneration independent of intraocular pressure. Early
intervention combining pressure-lowering and neuroprotective agents is critical for halting disease
progression. Pharmacologic neuroprotection targeting oxidative stress, mitochondrial dysfunction,
and excitotoxicity, coupled with gene therapy and stem cell research, provides a multidimensional
therapeutic platform. Translating preclinical advances into clinical success requires well-
structured trials, biomarker validation, and individualized treatment protocols. The future of
glaucoma therapy lies in integrating neuroprotection into standard care, thereby transforming the
disease course from inevitable vision loss to long-term visual stability.
References
1.
БЕЛКА, F. S. Р. С. Р. (2022). В ПАТОГЕНЕЗЕ СОСУДИСТЫХ ЗАБОЛЕВАНИЙ
ОРГАНА ЗРЕНИЯ У БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ.
2.
Жалалова, Д. З., Кадирова, А. М., & Хамракулов, С. Б. (2021). Исходы герпетических
кератоувеитов на фоне лечения препаратом «офтальмоферон» в зависимости от
иммунного статуса пациентов. междисциплинарный подход по заболеваниям
органов головы и шеи, 103.
3.
ЖД, З., and А. БС. "РЕЗУЛЬТАТЫ ОЦЕНКИ УРОВНЯ ЭНДОТЕЛИНА-1 И Д-
ДИМЕРОВ В СЛЕЗНОЙ ЖИДКОСТИ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ
ГИПЕРТЕНЗИЕЙ." SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL
SCIENCES 3.3 (2024): 300-307.
4.
Zhalalova, D. Z. OCT angiography in the assessment of retinal and choreoretinal
microcirculation in patients with uncomplicated arterial hypertension International
Ophthalmological Congress IOC Tashkent 2021.
5.
Zhalalova, D. Z. Evaluation of markers of endothelial dysfunction in tear fluid in patients
with arterial hypertension. Journal of Biomedicine in Amaliet. Tashkent-2022, Volume
No., No. WITH.
6.
Жалалова, Д. З. (2021). Эндотелин-1 ва гомоцистеин даражасини артериал
гипертензия фонида тур пардв узгаришларида эндотелиал дисфункциянинг
маркерлари сифатида текшириш. Биомедицина ва амалиет журнали, 6(5), 203-210.
7.
Jalalova, D., Axmedov, A., Kuryazov, A., & Shernazarov, F. (2022). Combined dental and
eye pathology. Science and innovation, 1(8), 91-100.
8.
Zhalalova, D. Z. (2022). Pulatov US MICROCIRCULATORY DISORDERS IN THE
VASCULAR SYSTEM OF THE BULBAR CONJUNCTIVA WITH INITIAL
MANIFESTATIONS OF INSUFFICIENT BLOOD SUPPLY TO THE BRAIN. European
journal of molecular medicine, 2(5).
9.
Жалалова, Д. З. (2021). ОКТ-ангиография при оценке сосудистого русла сетчатки и
хориоидеи. Биология ва тиббиет муаммолари, 6(130), 211-216.
10.
Жалалова, Д. З. (2022). Классификационые критерии изменений сосудов сетчатки
при артериальной гипертензии. In Международная научная конференция
Университетская наука: взгляд в будущее (pp. 56-64).
Noyabr, 2025-Yil
97
11.
Долиев, М. Н., Тулакова, Г. Э., Кадырова, А. М., Юсупов, З. А., & Жалалова, Д. З.
(2016). Эффективность комбинированного лечения пациентов с центральной
серозной
хориоретинопатией.
Вестник
Башкирского
государственного
медицинского университета, (2), 64-66.
12.
Жалалова, Д. З. Оценка маркеров эндотелиальной дисфункции в слезной жидкости у
пациентов с артериальной гипертензиейЖурнал «Биомедицина ва амалиет».
Тошкент-2022, Том №, №. С.
13.
Жалалова, Д. З. (2021). ОКТ-ангиография в оценке ретинальной и хореоретинальной
микроциркуляции у пациентов с неосложненой артериальной гипертензией/I
Международный офтальмологческий конгресс IOC Uzbekistan, 2021 г. Ташкент, с, 96.
14.
Shernazarov, F., Jalalova, D., Azimov, A., & CAUSES, S. A. (2022). SYMPTOMS,
APPEARANCE, TREATMENT OF VARICOSE VEINS.
15.
Жалалова, Д. З. (2021). Эндотелин-1 ва гомоцистеин даражасини артериал
гипертензия фонида тур пардв узгаришларида эндотелиал дисфункциянинг
маркерлари сифатида текшириш. Биомедицина ва амалиет журнали, 6(5), 203-210.
16.
Shernazarov, F., Tohirova, J., & Jalalova, D. (2022). Types of hemorrhagic diseases,
changes in newboens, their early diagnosis. Science and innovation, 1(D5), 16-22.
17.
Zhalalova, D. Z. (2022). The content of endothelin and homocysteine in blood and lacrimal
fluid in patients with hypertensive retinopathy Web of Scientist: International Scientific
Research Journal. ISSUE, 2, 958-963.
18.
Shernazarov, F., & Zuhridinovna, J. D. (2022). Microcirculation disorders in the vascular
system of the bulbar conjunctiva in the initial manifestations of cerebral blood supply
deficiency. Science and innovation, 1(Special Issue 2), 515-522.
19.
Zhalalova, D. Z. (2022). Modern aspects of neuroprotektive treatment in hypertensive
retinopathy Web of Scientist: International Scientific Research JournalVolume 3. ISSUE, 2,
949-952.
20.
Жалалова, Д. З. (2009). Метод комбинированного лечения диабетической
ретинопатии. Врач-аспирант, 37(10), 864-868.
21.
Жалалова, Д. З. (2023). Результаты оценки эффективности комплексного лечения у
пациентов с 3-4 стадиями гипертонической ангиоретинопатии. Miasto Przyszłości, 41,
33-36.
22.
ЖД, З., & ИЖ, Ж. (2024). КЛАССИФИКАЦИЯ ГИПЕРТОНИЧЕСКОЙ
РЕТИНОПАТИИ НА ОСНОВЕ ДАННЫХ ОПТИЧЕСКОЙ КОГЕРЕНТНОЙ
ТОМОГРАФИИ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES,
3(3), 336-342.
23.
ЗЖД, Ж. (2024). КЛИНИКО-ФУНКЦИОНАЛЬНЫЕ ПОКАЗАТЕЛИ ОРГАНА
ЗРЕНИЯ У ПАЦИЕНТОВ С ИШЕМИЧЕКИМИ ИЗМЕНЕНИЯМИ СОСУДОВ
СЕТЧАТКИ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3),
286-293.
24.
ЖД,
З.
(2024).
ОЦЕНКА
КЛИНИЧЕСКИХ
И
ФУНКЦИОНАЛЬНЫХ
ПОКАЗАТЕЛЕЙ ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ В СЛЕЗНОЙ ЖИДКОСТИ
Noyabr, 2025-Yil
98
У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. SCIENTIFIC JOURNAL OF
APPLIED AND MEDICAL SCIENCES, 3(3), 330-335.
25.
Жалалова, Д. З. (2023). Актуальность проблемы изменений глазного дна при
артериальной гипертензии. Miasto Przyszłości, 41, 37-40.
